What We Do

As countries advance and move away from vertically funded (be it domestic or external) interventions, the integration of those programs into broader national systems is an important step.

We help to address the potential challenges during this transition.

• Designing a seamless process, thus ensuring the ongoing treatment of patients is not affected
• Merging and readjusting budgets when funding streams of previous vertical programs change
• Political economy and governance questions of integration and transition

We offer

• Practical capacity building in form of training, materials and practical case studies for stakeholders
• Development of capacity building strategies, including local capacity assessment, gap analysis and feaseable solutions for institutional and individual capacity development

Despite the broad range of information available and the technical possibilities for reach-out, no medium can replace a peer-to-peer exchange on a burning question.

• Through our broad international network, we provide confidential and reliable linkages among stakeholders such as payers, ministries and other relevant institutions around the globe.
• This unique feature of our services will guarantee the access to real, hands-on and most up-to date approaches in handling challenges in our field.

Patents, pricing, supply chain management, procurement, HTA… Pharmaceutical policy is a broad field with a variety of system questions. Specifically when moving towards UHC, a coherent approach is needed to ensure a system and the payer behind it can deliver access but also remain sustainable.

In our approach, we apply a specific framework to interlink the essential functions, connecting the dots and assuring access.

• In depth evaluation of the pharmaceutical system, mapping of stakeholders and analysis of pharmaceutical policies
• Starting from manufacturers and regulatory authorities up to the health care payers (e.g. national health insurances) and the patients
• Specific focus lies on stakeholders’ interactions and the decision-making flow in the system

Design of financially sustainable (pharmaceutical) benefit packages: as UHC develops, there is mounting pressure to develop comprehensible pharmaceutical packages that integrate latest breakthrough medicines.

We support the development of evaluation practices and transparent methodologies for inclusion of new technologies, and limiting their potential budget impact through early identification of users and monitoring of physician prescribing.

• Support for country tailored evidence based reimbursement decision-making (data requirements, data exchange and data analysis) and use of adapted methodologies for health technology assessment
• Advice on pharmaceutical cost management and cost containment (support on development of health economics models, design of pricing negotiation guidelines, budget impact etc.)
• Design of hands on step-by-step strategies for policy makers and international organizations to manage public-private partnerships (e.g. early advice on locally required medicines, support for specific disease areas etc)
• Practical recommendations on how to improve the decision making process within the existing framework of institutions

As the benefit package is never in a steady state, we help to design country tailored governance structures and processes for:

• Ongoing evaluation and adjustment of the package or reimbursement list
• Decision making for incoming new (and often high cost) interventions
• Dealing with practical implications of de-listing and exclusion of interventions or products

Based on international best practices we provide the tools to price products based on local realities such as

• Affordability and ability to pay
• Local capacities
• Local market and supply specifics

Moreover, we offer hands-on guidance on managing the public-private interface of pricing, such as negotiations, managed-entry agreements and payment approaches.